Novel Drug-Like Somatostatin Receptor 4 Agonists are Potential Analgesics for Neuropathic PainBoglárka Kántás, Zsuzsanna Helyes, Rita Börzsei et al.|International Journal of Molecular Sciences|2019Cited by 31
Analgesic Effects of Lipid Raft Disruption by Sphingomyelinase and Myriocin via Transient Receptor Potential Vanilloid 1 and Transient Receptor Potential Ankyrin 1 Ion Channel ModulationÁdám Horváth, Éva Szőke, Tünde Biró-Süt et al.|Frontiers in Pharmacology|2021Cited by 21
Antinociceptive Effects of Lipid Raft Disruptors, a Novel Carboxamido-Steroid and Methyl β-Cyclodextrin, in Mice by Inhibiting Transient Receptor Potential Vanilloid 1 and Ankyrin 1 Channel ActivationÁdám Horváth, Éva Szőke, Tünde Bíró-Sütő et al.|Frontiers in Physiology|2020Cited by 15
In Silico, In Vitro and In Vivo Pharmacodynamic Characterization of Novel Analgesic Drug Candidate Somatostatin SST4 Receptor AgonistsBoglárka Kántás, Zsuzsanna Helyes, Éva Szőke et al.|Frontiers in Pharmacology|2021Cited by 11
The heptapeptide somatostatin analogue TT-232 exerts analgesic and anti-inflammatory actions via SST4 receptor activation: In silico, in vitro and in vivo evidence in miceRita Börzsei, Erika Pintér, Éva Borbély et al.|Biochemical Pharmacology|2023Cited by 11